Avego Management LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Avego Management LLC
CRD #310520
SEC #801-120171
CIK #0001886177
AUM 917.5 M (2026-03-31)
Employees 16 (75% Investors, 0% Brokers)
Fees
Minimum
Phone646-844-0030
Address100 North Main Street
Alpharetta, GA 30009
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($M)
110088066044022002010201520212027
Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure]
Item 5.    Fees and Compensation

The Adviser’s fees and compensation are described in each client’s Governing Documents. All of the
Firm’s clients are expected to be “qualified purchasers” (as defined in Section 2(a)(51) of the Investment
Company Act of 1940, as amended).

Fees Generally

Management Fees and Performance-Based Compensation. The management fee (the “Management
Fee”) and performance-based compensation rates for the Funds are disclosed in each Fund’s Governing
Documents.

The Funds will pay the Adviser a Management Fee quarterly in advance based on Fund investor capital
commitments with respect to one of the closed end funds, or the value of Fund investor capital accounts
with respect to open end funds. Management Fees are prorated in the case of a partial calendar quarter.
The Adviser may elect to reduce, otherwise modify or waive the Management Fee with respect to any of
its affiliates, Fund investor, and the Adviser’s employees, in accordance with the Fund’s governing
documents.

An affiliate of the Adviser that serves as the general partner of a Fund (the “General Partner”) will be paid
performance-based compensation by the Funds, which is compensation that is based on a share of capital
gains on or capital appreciation of the assets of the Funds.

Expenses Generally

Investors in the Funds should carefully review the expense provisions in their applicable Fund Governing
Documents for a complete description of such Fund’s expense practices.

Each Fund is responsible for expenses incurred by it and related to its activities, including (as more fully
defined in the Governing Documents) but not limited to: the Management Fee; Fund legal, compliance
(including consultants’ fees), placement fees, risk management expenses (including software licensing

and consultants’ fees), administrator (including, but not limited to, middle and back office services and
software necessary for trade capture and portfolio management), audit and tax preparation (including third-
party tax preparation), and accounting expenses (including third party accounting services and accounting
software); all costs and expenses of any custodians, attorneys, accountants, auditors, tax advisors,
brokers, agents, research related data providers, valuation experts or other advisors or professionals
relating to the affairs of the Fund; organizational expenses; execution and order management system fees
and expenses; investment expenses such as omissions, research-related fees and expenses (including
Bloomberg and similar subscriptions and data services, expenses incurred in connection with multimedia,
analytical, database, news or other third-party research services as well as related terminals for the
delivery of such services, artificial intelligence tools used for research and research-related travel
(including meals and lodging)); interest on margin accounts and other indebtedness; borrowing charges
on securities sold short; custodial fees; bank service fees; all costs and expenses of any litigation,
threatened litigation, indemnification or other extraordinary expenses or liabilities relating to the affairs of
the Fund; Fund-related insurance costs (D&O and E&O insurance); independent master fund governance
committee members’ fees and expenses; expenses of regulatory compliance (including compliance with
AIFMD and AEOI), filings and reporting (including but not limited to Section 13, Section 16 and Form PF
filings); all costs and expenses incurred in connection with complying with Anti-Money Laundering laws,
“know your customer” laws and Foreign Account Tax Compliance Act (“FATCA”), including the fees and
expenses of third-party service providers related to such compliance; costs and expenses incurred in
connection with complying with provisions in Governing Documents and/or side letter agreements or
similar agreements; unreimbursed costs and expenses incurred in connection with any transfer or
proposed transfer or any default by a limited partner; expenses incurred in connection with the managed
distribution of marketable securities; costs and expenses of any lenders and other financing sources, and
principal and interest on, and fees and expenses arising out of, all borrowings made by the Fund, including,
without limitation, the arranging, negotiating, structuring, entering into and amending thereof; directors’
fees (including the fees and expenses of independent master fund governance committee members
directly related to their service as directors of the offshore fund); pricing service fees; all costs and
expenses of winding-up and dissolving the Fund and any alternative investment vehicles; all expenses
incurred in connection with any tax, audit, investigation, settlement, or review of the Fund; portfolio
valuation expenses (including data feeds and third-party valuation agents); and any other expenses related
to the purchase, sale or transmittal of Fund assets.

Allocation of Expenses. Each Fund bears expenses as set forth in its respective Governing Documents.
Common expenses may be incurred on behalf of the Funds. The Adviser would seek to allocate those
common expenses among the Funds in a manner that would be fair and reasonable over time and in
accordance with the relevant Governing Documents. As the allocation of expenses by the Adviser
represents a conflict of interest, the Adviser has adopted an expense allocation policy that is designed to
address this conflict. The Adviser may use various methods to allocate expenses among the Funds
depending on the circumstances (e.g., pro rata based on assets under management, relative participation
in the transaction related to the expense, general amount of trading activity etc.). The determination as to
the method or methods used may be based on relative use of the product or service, the nature or source
of the product or service, the relative benefits derived by each of the Funds from the product or service, or
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure]
Item 7.     Types of Clients

The Adviser’s clients consist of the Funds. Investors in the Funds are generally high net worth individuals
and institutional investors that qualify as “accredited investors” (as defined in Rule 501 under the Securities
Act of 1933, as amended) and qualified purchasers. The minimum initial investment in the Funds will be
determined by the Adviser. The Adviser has waived such minimum and may, in its discretion, do so in the
future under certain circumstances.
Type Form D Funds Date Sold AUM
HF Velan Capital Opportunity Fund II LLC [2026-03-30] 2.4 M 1.8 M
Filed 2025-03-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
HF Velan Horizon Fund LP 2025-03-28 9.1 M
PE Ahc-II AGR Partners LP [2024-03-28] 29.5 M
Filed 2023-05-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
HF Velan Capital SPV I LLC [2024-03-28] 5.5 M 18.1 M
Filed 2023-06-22 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Avego Healthcare Capital Fund II LP [2023-03-31] 278.1 M 366.4 M
Filed 2023-10-12 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $1,999,375 · Revenue Decline to Disclose
HF Velan Capital Master Fund LP [2023-03-31] 11.7 M 256.1 M
Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Velan Capital Offshore Fund Ltd [2023-03-31] 11.7 M
Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
VC Avego Bioscience Capital LP [2022-03-31] 68.7 M 92.4 M
Filed 2025-03-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE Avego Healthcare Capital LP [2020-12-16] 109.4 M 162.2 M
Filed 2024-11-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $122,900 · Revenue Decline to Disclose
HF Velan Capital Partners LP [2020-12-16] 11.7 M 143.9 M
Filed 2025-11-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
View All
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 9 917.5
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 9 917.5
By Discretionary
Discretionary 9 917.5
Non-Discretionary 0 0.0
Total 9 917.5
By Non-United States Persons
Non-United States Persons 256.1
United States Persons 661.4
Total 9 917.5
Form D Directors Role # Filings # Firms 2011 - 2026
Thomas Vandervort Executive Officer 6 2
James Flexner Executive Officer 4 2
Velan Capital Investment Management LP Executive Officer 3 1
Velan Capital Holdings LLC Executive Officer 3 1
Balaji Venkataraman Executive Officer 2 1
Avego Management LLC Executive Officer 2 1
Avego Healthcare Capital GP II LLC Director 2 1
Kevin McNeill Executive Officer 2 1
Avego Bioscience Capital GP LLC Executive Officer 1 1
Avego Healthcare Capital Holdings LLC Executive Officer 1 1
James Zenker Executive Officer 1 1
Alyssa Romano Executive Officer 1 1
Velan Capital Invesment Management LP Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
3 [0001886177]
4 [0001886177]
SC 13G [0001886177]
Form 13D/13G Filer Form 13D/13G Subject Filed
Avego Management LLC Jasper Therapeutics Inc [2021-10-04]
Firm Profile (Form ADV)
Discretionary AUM$0.3B
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI2549009SHB59XHUX6731
Form 3/4/5 Subject 2011 - 2026
Velan Capital Investment Management LP
Avego Management LLC
Morgan Adam
Avego Healthcare Capital Holdings LLC
Venkataraman Balaji
Velan Capital Management LLC
Amplitude Healthcare Acquisition Corp
Avego Healthcare Capital LP
Velan Capital Master Fund LP
Velan Capital Holdings LLC
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Amplitude Healthcare Acquisition Corp JSPR
Common Stock, par value $0.0001 per share
2024-02-08 Buy 350,000 $12.95 4,532,500
Comparable Firms State AUM
EOS Management LP
NY 957.1 M
ThornTree Capital Partners LP
MA 955.3 M
HCSF Management LLC
NY 949.4 M
Dalal Street LLC
TX 936.3 M
Toscafund Asset Management LLP
933.3 M
Sandalwood Securities Inc
NJ 930.2 M
Extract Advisors LLC
CA 914.4 M
Yorkville Advisors Global LP
NJ 900.0 M
Bow Street LLC
NY 884.7 M
Sandglass Capital Advisors LLC
NY 873.7 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com